Event: Q2 2026 earnings call on Wednesday, August 5, 2026
Core setup: Insulet enters the quarter with a strong operating-growth story but a more demanding burden of proof: investors will look for confirmation that U.S. new-customer-start momentum recovered after a seasonally soft Q1, international growth remains durable as comparisons tighten, and the March product correction is contained financially and operationally.
Management’s Q2 outlook calls for 20%–22% constant-currency total-company growth. Including the approximately one-point FX tailwind assumed in the guide, that implies roughly 21%–23% reported growth.
| Q2 2026 guide | Q2 2025 actual | Implied Q2 2026 revenue |
|---|---|---|
| Total company | $649.1M | $785M–$798M |
| U.S. Omnipod | $453.2M | $535M–$544M |
| International Omnipod | $185.8M | $242M–$245M |
| Drug Delivery | $10.2M | Approximately $5M |
The headline growth rate is expected to decelerate from Q1’s 30.1% constant-currency growth, but that is largely anticipated. Q1 benefited from exceptional international growth and approximately $10M of U.S. distributor-order timing that management said would reverse in Q2—roughly a 200-basis-point headwind to Q2 U.S. growth.
Read-through: A result near the high end of guidance—or above it—would support the argument that Q1’s U.S. start softness was temporary rather than competitive or demand-related.
In Q1, U.S. Omnipod revenue grew 28.3%, or roughly 26% excluding order timing, but sequential new-customer starts declined due to what management described as a more pronounced deductible-reset / copay seasonality effect. Management said starts improved month by month through Q1 and into April.
For Q2, investors should focus less on reported revenue alone and more on commentary around:
The type 2 opportunity remains fundamental to the long-term thesis. Management indicated that approximately 40% of Q1 new customer starts were type 2, while also acknowledging that retention can be modestly lower early in the type 2 patient journey. The investment question is not whether type 2 adds growth today—it clearly does—but whether Insulet can improve onboarding and early retention sufficiently to make that growth increasingly valuable over time.
What would be bullish: Clear confirmation of year-over-year U.S. starts growth, continued type 2 momentum, stable utilization, and no sign that competitive pharmacy activity is forcing price concessions.
What would concern investors: Another explanation for weak starts, a deterioration in type 2 retention beyond expectations, or a more cautious tone on U.S. net pricing/access.
International Omnipod revenue grew 45.2% constant currency in Q1, the company’s third consecutive quarter above 40% growth. The drivers were broad-based new-customer-start growth, Omnipod 5 adoption, and favorable price/mix as customers transition from DASH to Omnipod 5.
For Q2, management guided to 28%–30% constant-currency international growth, with a roughly two-point FX benefit on a reported basis. The expected moderation is principally a comparison and mix issue, not an indication that the international growth engine has broken:
Key earnings-call question: Is the guided moderation solely due to tougher comparisons and reduced DASH-to-Omnipod-5 mix benefit, or has underlying new-customer-start momentum slowed as well?
PODD’s Q1 adjusted operating margin expanded 110 bps year over year to 17.5%, even as the company increased R&D and commercial spending. For full-year 2026, management still targets approximately 100 bps of adjusted operating-margin expansion and adjusted EPS growth of more than 25%.
However, Q2 margin quality deserves attention because of three offsetting factors:
Tailwinds - High recurring-revenue mix - Manufacturing productivity - Positive U.S. net pricing - International scale and operating leverage
Headwinds - Ongoing sales-force expansion and demand-generation investment - Higher R&D spend for Omnipod 6 and the type 2 fully closed-loop program - Incremental raw-material and shipping costs - Medical-device-correction expenses and manual quality inspections
The March correction related to certain U.S. Omnipod 5 lots with a potential internal-tubing issue. Insulet estimated total correction-related costs of approximately $30M, with more than half expected in 2026. Q1 included $11.7M of estimated warranty expense, while manual inspections are expected to continue until automated inspection systems are implemented.
The issue for Q2: Investors will want a clean update on correction costs, manufacturing actions, FDA/regulatory status, complaint trends, and whether the event has affected prescriber confidence, new starts, or supply availability. Management previously said it did not expect shipment disruption or an impact on Q1 new starts.
The Q2 period was expected to include the broader U.S. launch of:
The Libre 3 Plus integration is strategically important because management estimates it opens Omnipod 5 to nearly 450,000 people using that sensor in the U.S. Commentary on launch timing, early uptake, prescriber response, and reimbursement will matter more than any immediate revenue contribution.
These are not near-term Q2 revenue drivers, but they underpin the longer-duration growth case:
The strategic value is significant: a more automated, simpler experience could improve access to the far larger type 2 insulin population and expand prescribing beyond specialist settings.
PODD raised FY26 total-company constant-currency growth guidance after Q1 to 21%–23%, with Omnipod growth of 22%–24%. The pieces are:
| FY26 constant-currency outlook | Current guide |
|---|---|
| U.S. Omnipod growth | 20%–22% |
| International Omnipod growth | 26%–28% |
| Total Omnipod growth | 22%–24% |
| Total company growth | 21%–23% |
| Adjusted operating margin | ~100 bps expansion |
| Adjusted EPS growth | >25% |
A raise is possible if Q2 again materially exceeds expectations, particularly because Q1 was well ahead of its initial framework. But investors should not assume one: management has emphasized that the second half faces tougher comparisons and that first-half versus second-half growth is affected by FX and the timing of international mix benefits.
More important than a formal raise: whether management reiterates confidence in sustaining its longer-term ~20% growth framework as it exits 2026.
PODD closed at $166.85 on August 4, 2026. The stock is down roughly 42% over the past year and about 41% year to date, despite a roughly 20% rebound from its June 22 low.
That price action suggests the market is discounting more than merely a quarterly revenue beat/miss. The report needs to address the broader concerns around:
The Q2 bar is not simply beating a $785M–$798M implied revenue range. A constructive report needs to demonstrate that U.S. starts rebounded after Q1 seasonality, international growth is moderating for expected—not structural—reasons, the correction remains contained, and product launches are progressing as planned.
The favorable setup is that management has multiple levers—type 2 adoption, international penetration, Libre 3 Plus integration, algorithm upgrades, positive net pricing, and a recurring-disposable revenue model. The risk is that the market now requires evidence that these levers can outweigh quality-related scrutiny, a normalization in international mix, and intensifying competition.
Most important call takeaways: U.S. new-customer-start trajectory, type 2 retention, correction-cost/run-rate outlook, Libre 3 Plus launch update, international underlying volume versus mix, and the confidence level behind FY26 guidance.
Sources: Insulet Q1 2026 earnings release, Q1 2026 earnings-call transcript, Q1 2026 Form 10-Q, March 12, 2026 medical-device-correction announcement, Q2 2025 earnings release, and historical share-price data through August 4, 2026.